- Title
- Serum amyloid A opposes lipoxin A4 to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease
- Creator
- Bozinovski, Steven; Uddin, Mohib; Anderson, Gary P.; Vlahos, Ross; Thompson, Michelle; McQualter, Jonathan L.; Merritt, Anne-Sophie; Wark, Peter A. B.; Hutchinson, Anastasia; Irving, Louis B.; Levy, Bruce D.
- Relation
- National Academy of Sciences: Proceedings Vol. 109, Issue 3, p. 935-940
- Publisher Link
- http://dx.doi.org/10.1073/pnas.1109382109
- Publisher
- National Academy of Sciences
- Resource Type
- journal article
- Date
- 2012
- Description
- Chronic obstructive pulmonary disease (COPD) will soon be the third most common cause of death globally. Despite smoking cessation, neutrophilic mucosal inflammation persistently damages the airways and fails to protect from recurrent infections. This maladaptive and excess inflammation is also refractory to glucocorticosteroids (GC). Here, we identify serum amyloid A (SAA) as a candidate mediator of GC refractory inflammation in COPD. Extrahepatic SAA was detected locally in COPD bronchoalveolar lavage fluid, which correlated with IL-8 and neutrophil elastase, consistent with neutrophil recruitment and activation. Immunohistochemistry detected SAA was in close proximity to airway epithelium, and in vitro SAA triggered release of IL-8 and other proinflammatory mediators by airway epithelial cells in an ALX/FPR2 (formyl peptide receptor 2) receptor-dependent manner. Lipoxin A4 (LXA,sub>4) can also interact with ALX/FPR2 receptors and lead to allosteric inhibition of SAA-initiated epithelial responses (pA2 13 nM). During acute exacerbation, peripheral blood SAA levels increased dramatically and were disproportionately increased relative to LXA4. Human lung macrophages (CD68⁺) colocalized with SAA and GCs markedly increased SAA in vitro (THP-1, pEC50 43 nM). To determine its direct actions, SAA was administered into murine lung, leading to induction of CXC chemokine ligand 1/2 and a neutrophilic response that was inhibited by 15-epi-LXA4 but not dexamethasone. Taken together, these findings identify SAA as a therapeutic target for inhibition and implicate SAA as a mediator of GC-resistant lung inflammation that can overwhelm organ protective signaling by lipoxins at ALX/FPR2 receptors.
- Subject
- resolution; leukocyte activation; G protein-coupled receptor; innate immunity
- Identifier
- http://hdl.handle.net/1959.13/1319033
- Identifier
- uon:23760
- Identifier
- ISSN:0027-8424
- Language
- eng
- Reviewed
- Hits: 12586
- Visitors: 12557
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|